Bev G wrote:Hi Doc...My husband ... doesn't think he will ever be able to operate again. I suspect you have considered that as a potential problem from the FOLFOX. I wonder if you or your docs have considered treating you with FOLFIRI instead of FOLFOX to mitigate some of that risk? Bev
Hello plastiko -
Welcome to this board. It's terrible that you have to be here at such an early age, but it's good that you have registered here so soon and that you have already updated your signature. This will enable you to connect with specific members here who can give you support in your particular diagnostic context (mCRC - KRAS wild).
Although I do not have a medical background, I would like to support the suggestion made earlier by Bev G, namely that you consider a FOLFIRI based regime rather than a FOLFOX-based regime as a first-line therapy for your type of mCRC
The NCCN organization publishes a list of recommended first-line ('standard-of-care') therapies for all kinds of colon cancer at different stages, and you can download a copy of your own to review at your leisure.(You must first register on their site to do this.) The document you would want to access is:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, Version 2.2015, 143pphttp://www.nccn.org/professionals/physician_gls/pdf/colon.pdfThis is a 143 page document, and on pages 25-27 the document gives the decision tree for deciding first line therapy for mCRC patients. What you see there is that the chemo regimen that they put you on is indeed one of the recommended ones:
FOLFOX + cetuximab (for KRAS/ WT gene) -- on p 25, lower left branch of decision tree
However, it is not the only one available in your case, and on the following page you will find the regimen that Bev G is referring to. This one is:
FOLFIRI + cetuximab (for KRAS/ WT gene) -- on p 26, lower left branch of decision tree
The fine detail of these regimens (dosage, timing, cycles, etc.) is given later on page 30 (upper right-hand panel) and page 31 (lower left-hand panel), respectively.
In your case, I think the second of these regimens would be preferable because it would allow you to escape the long-term effects of permanent peripheral neuropathy that usually accompany any regimen containing Oxaliplatin, i.e., any regimen containing OX in the title.
So, my suggestion would be to print off the relevant pages of the NCCN Guideline and discuss this with your oncologist and see what might be the best course of action for you to take.
.
OSM